Effect of HER2-targeted therapy on PDX and PDX-derived organoids generated from HER2-positive salivary duct carcinoma

被引：2
|
作者：
Aoyama, Jun [1 ]
Nojima, Yusuke [1 ]
Sano, Daisuke [1 ,2 ,3 ]
Hirai, Yuri [1 ]
Kijima, Natsumi [1 ]
Aizawa, Yoshihiro [1 ]
Takada, Kentaro [1 ]
Hatano, Takashi [1 ]
Takahashi, Hideaki [1 ]
Nishimura, Goshi [1 ]
Oridate, Nobuhiko [1 ,2 ]
机构：
[1] Yokohama City Univ, Grad Sch Med, Dept Biol & Funct Head & Neck, Yokohama, Japan
[2] Yokohama City Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Yokohama, Japan
[3] Yokohama City Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 3-9 Fukuura,Kanazawa Ku, Yokohama 2360004, Japan
来源：
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2023年 / 45卷 / 07期
基金：
日本学术振兴会;
关键词：
HER2; lapatinib; patient-derived organoid; salivary duct carcinoma; salivary gland cancer; FACTOR RECEPTOR EGFR; LAPATINIB; BREAST; TRASTUZUMAB; RESISTANCE; INHIBITOR; GW572016; HEAD;
D O I：
10.1002/hed.27395
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
BackgroundWe previously established a patient-derived xenograft (PDX) model, patient-derived organoids (PDOs), and PDX-derived organoids (PDXOs) for salivary duct carcinoma (SDC). Using these models, this study examined the therapeutic effect of human epidermal growth factor receptor 2 (HER2) blockade on HER2-positive SDC. MethodsThe therapeutic effect of lapatinib was assessed in SDC PDXOs with regards to cell growth, receptor/downstream signaling molecule expression, phosphorylation levels, and apoptosis. Effect of lapatinib treatment was evaluated in vivo in SDC PDX mice. ResultsThe siRNA knockdown of HER2 and lapatinib suppressed cell proliferation in SDC PDXOs. Lapatinib inhibited the phosphorylation of HER2 and its downstream targets, and induced apoptosis in SDC PDXOs. Lapatinib also significantly reduced tumor volumes compared with that of the control in SDC PDX mice. ConclusionFor the first time, we demonstrated the efficacy of anti-HER2 therapy in HER2-positive SDC using preclinical models of SDC PDX and PDXO.
引用
收藏
页码：1801 / 1811
页数：11
相关论文
共 50 条
  • [41] A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE
    Hodeib, Melissa
    Serna-Gallegos, Tasha
    Tewari, Krishnansu S.
    FUTURE ONCOLOGY, 2015, 11 (23) : 3113 - 3131
  • [42] Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
    Toomey, Sinead
    Eustace, Alexander J.
    Fay, Joanna
    Sheehan, Katherine M.
    Carr, Aoife
    Milewska, Malgorzata
    Madden, Stephen F.
    Teiserskiene, Ausra
    Kay, Elaine W.
    O'Donovan, Norma
    Gallagher, William
    Grogan, Liam
    Breathnach, Oscar
    Walshe, Janice
    Kelly, Catherine
    Moulton, Brian
    Kennedy, M. John
    Gullo, Guiseppe
    Hill, Arnold D.
    Power, Colm
    Duke, Deirdre
    Hambly, Niamh
    Crown, John
    Hennessy, Bryan T.
    BREAST CANCER RESEARCH, 2017, 19
  • [43] A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer
    Xie, Bao-jie
    Zhu, Li-na
    Ma, Can
    Li, Ji-bin
    Dong, Lei
    Zhu, Zhong-ning
    Ding, Tao
    Gu, Xin-shun
    BREAST CANCER, 2020, 27 (02) : 186 - 196
  • [44] Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
    Gunasekara, Agampodi Danushi Mendis
    Youngkong, Sitaporn
    Anothaisintawee, Thunyarat
    Dejthevaporn, Thitiya
    Fernandopulle, Rohini
    Chaikledkaew, Usa
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [45] Synergistic Effect of the Combined Action of Targeted and Photodynamic Therapy on HER2-Positive Breast Cancer
    Balalaeva, I. V.
    Krylova, L. V.
    Karpova, M. A.
    Shulga, A. A.
    Konovalova, E. V.
    Guryev, E. L.
    Deyev, S. M.
    DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2022, 507 (01) : 330 - 333
  • [46] Dual-targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab
    Shu, Mengjun
    Gao, Feng
    Yu, Chulang
    Zeng, Min
    He, Guili
    Wu, Yan
    Su, Yanjie
    Hu, Nantao
    Zhou, Zhihua
    Yang, Zhi
    Xu, Lin
    NANOTECHNOLOGY, 2020, 31 (33)
  • [47] Recent advances in nanoscale targeted therapy of HER2-positive breast cancer
    Omidi, Yadollah
    Mobasher, Maha
    Castejon, Ana M.
    Mahmoudi, Morteza
    JOURNAL OF DRUG TARGETING, 2022, 30 (07) : 687 - 708
  • [48] HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy
    Shao, Qiangzu
    Deng, Junge
    Wu, Haoran
    Huang, Zeping
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [49] Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy
    Whitworth, Pat W.
    Beitsch, Peter D.
    Murray, Mary K.
    Richards, Paul D.
    Mislowsky, Angela
    Dul, Carrie L.
    Pellicane, James V.
    Baron, Paul L.
    Rahman, Rakhshanda Layeequr
    Lee, Laura A.
    Dupree, Beth B.
    Kelemen, Pond R.
    Ashikari, Andrew Y.
    Budway, Raye J.
    Lopez-Penalver, Cristina
    Dooley, William
    Wang, Shiyu
    Dauer, Patricia
    Menicucci, Andrea R.
    Yoder, Erin B.
    Finn, Christine
    Blumencranz, Lisa E.
    Audeh, William
    JCO PRECISION ONCOLOGY, 2022, 6
  • [50] An Evaluation of HER2-Positive Ovarian Carcinoma Xenografts: From a Novel Therapy to a Noninvasive Monitoring Method
    Hong, Zhihui
    Mao, Xinping
    You, Jiaxi
    Liu, Zengli
    Shi, Yizhen
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2018, 33 (09) : 411 - 419
12345